Add this topic to your myFT Digest for news straight to your inbox
Revised offer by Japanese drugmaker accepted by board after weeks of negotiation
The Takeda-Shire deal shows companies are buying overseas assets while they still can
Deutsche Bank trims US operations; Shire, WhatsApp, SoftBank and Capita in the news
Moves highlight new potential hypocrisies for dealing with cross-border transactions
Analysts say Japanese drugmaker has few alternatives left if it is to compete globally
Japanese company to join top ranks of global pharma groups
Only low Japanese interest rates make the numbers work in this deal
Japanese company makes its biggest bet to join the top ranks of global pharma groups
Takeda’s offer to pay $65bn for Shire comes amid a rush of M&A deals in healthcare
UK rare diseases drug company had rebuffed three previous proposals
Japanese pharma group’s latest proposal includes higher cash component
Japanese drugmaker also increases the cash component of the offer
Shares in Irish drugmaker yo-yo as US group says it may also bid, then pulls out
Botox maker eyes return to acquisition trail, but a tie-up would not add much value
Botox maker’s interest comes after Irish drugmaker rejects bid by Japan’s Takeda
Stock and cash offer values Irish drugmaker at £46.50 a share
International Edition